UK Dry Age Related Macular Degeneration Market

ID: MRFR/MED/43214-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026
UK Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals clinics, diagnostic centers, academic research institutes) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Dry Age Related Macular Degeneration Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)7.52%
2024 Market Size$ 199.92 Million
2025 Market Size$ 216.51 Million
2035 Market Size$ 443.94 Million

Key Players

Novartis AG
Regeneron Pharmaceuticals Inc
Roche Holding AG
Bayer AG
Allergan PLC
Apellis Pharmaceuticals Inc
Trends
  • Rising Prevalence of Dry AMD
  • Advancements in Treatment Options
  • Integration of Digital Health Solutions
Opportunities
  • Increasing Aging Population
  • Emerging Treatment Modalities
  • Rising Awareness and Education
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Disease Stage (USD Million)
      1. 4.1.1 Early Stage
      2. 4.1.2 Intermediate Stage
      3. 4.1.3 Late Stage
    2. 4.2 Healthcare, BY Treatment Type (USD Million)
      1. 4.2.1 Pharmacological Treatment
      2. 4.2.2 Surgical Intervention
      3. 4.2.3 Nutritional Supplements
    3. 4.3 Healthcare, BY Patient Demographics (USD Million)
      1. 4.3.1 Age Group
      2. 4.3.2 Gender
      3. 4.3.3 Socioeconomic Status
    4. 4.4 Healthcare, BY Healthcare Setting (USD Million)
      1. 4.4.1 Outpatient Clinics
      2. 4.4.2 Hospitals
      3. 4.4.3 Home Healthcare
    5. 4.5 Healthcare, BY Market Distribution Channel (USD Million)
      1. 4.5.1 Direct Sales
      2. 4.5.2 Online Sales
      3. 4.5.3 Pharmacies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis AG (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Regeneron Pharmaceuticals Inc (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche Holding AG (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bayer AG (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Allergan PLC (IE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Apellis Pharmaceuticals Inc (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Santen Pharmaceutical Co Ltd (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Zeiss Group (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY DISEASE STAGE
    3. 6.3 UK MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    5. 6.5 UK MARKET ANALYSIS BY HEALTHCARE SETTING
    6. 6.6 UK MARKET ANALYSIS BY MARKET DISTRIBUTION CHANNEL
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY DISEASE STAGE, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY DISEASE STAGE, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY MARKET DISTRIBUTION CHANNEL, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY MARKET DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE STAGE, 2026-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Million)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
      4. 7.2.4 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
      5. 7.2.5 BY MARKET DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Dry Age Related Macular Degeneration Market Segmentation

UK Dry Age Related Macular Degeneration Market By Disease Stage (USD Million, 2026-2035)

  • Early Stage
  • Intermediate Stage
  • Late Stage

UK Dry Age Related Macular Degeneration Market By Treatment Type (USD Million, 2026-2035)

  • Pharmacological Treatment
  • Surgical Intervention
  • Nutritional Supplements

UK Dry Age Related Macular Degeneration Market By Patient Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Socioeconomic Status

UK Dry Age Related Macular Degeneration Market By UK Dry Age Related Macular Degeneration Market Setting (USD Million, 2026-2035)

  • Outpatient Clinics
  • Hospitals
  • Home UK Dry Age Related Macular Degeneration Market

UK Dry Age Related Macular Degeneration Market By Market Distribution Channel (USD Million, 2026-2035)

  • Direct Sales
  • Online Sales
  • Pharmacies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035